ESR1 and breast carcinoma: This ensures the validity of the IGRN as well as the consistency and reliability of the analyses, deepening the understanding of the cellular mechanisms of macrophage/T cell-mediated malignant cells at the frontiers of ER+ breast cancer invasion, as well as informing the screening of patients for prognostic and therapeutic markers.